| P50 | author | Francis R LeBlanc | Q57190392 |
| P2093 | author name string | Xin Liu | |
| | Thomas P Loughran | |
| | Dan Zhang | |
| P2860 | cites work | The PI3K pathway as drug target in human cancer | Q24632283 |
| | Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling | Q24649116 |
| | T cell activation | Q24658051 |
| | Somatic STAT3 mutations in large granular lymphocytic leukemia | Q27851792 |
| | CD95's deadly mission in the immune system | Q28142072 |
| | Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia | Q28214577 |
| | NF-kappaB and the immune response | Q28271031 |
| | Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196 | Q28295592 |
| | Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression | Q28346555 |
| | Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation | Q28593921 |
| | Stats: transcriptional control and biological impact | Q29547776 |
| | STATs and gene regulation | Q29547796 |
| | The STATs of cancer--new molecular targets come of age | Q29614601 |
| | Hyperactive Ras in developmental disorders and cancer | Q29616397 |
| | Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways | Q30470153 |
| | A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 |
| | Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study | Q33382930 |
| | Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway | Q33579520 |
| | IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled | Q33941375 |
| | Role of Src expression and activation in human cancer | Q34103650 |
| | Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins | Q34115639 |
| | Sphingosine 1-phosphate, a key cell signaling molecule | Q34128454 |
| | Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved | Q34153221 |
| | The Stat family in cytokine signaling | Q34180677 |
| | Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia | Q34249759 |
| | FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma | Q34269804 |
| | Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia | Q34360352 |
| | Targeted Blockage of Signal Transducer and Activator of Transcription 5 Signaling Pathway with Decoy Oligodeoxynucleotides Suppresses Leukemic K562 Cell Growth | Q34541090 |
| | How I treat LGL leukemia | Q34707130 |
| | Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth | Q34922227 |
| | New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer | Q34975049 |
| | Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development | Q34995588 |
| | Platelet-derived growth factor signaling and human cancer | Q35051106 |
| | Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia | Q35212369 |
| | Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia | Q35651700 |
| | Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis | Q35849751 |
| | FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia | Q35945171 |
| | Regulation of immunity by lysosphingolipids and their G protein-coupled receptors | Q35971421 |
| | PI3K/AKT signaling and systemic autoimmunity | Q35980515 |
| | Activation-induced cell death in T cells and autoimmunity. | Q36283914 |
| | Antibody targeted drugs as cancer therapeutics | Q36373103 |
| | FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma | Q36384629 |
| | Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity | Q36400613 |
| | Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics | Q36418785 |
| | The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design | Q36547207 |
| | Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. | Q36685749 |
| | Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations | Q36742629 |
| | Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes | Q36787581 |
| | A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. | Q36835151 |
| | The metabolism and function of sphingolipids and glycosphingolipids. | Q36844738 |
| | Network model of survival signaling in large granular lymphocyte leukemia | Q36945148 |
| | T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias | Q37042046 |
| | Lipid signalling in disease. | Q37064018 |
| | The life of a cell: apoptosis regulation by the PI3K/PKB pathway | Q37289433 |
| | KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection | Q37362839 |
| | Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias | Q37452839 |
| | Farnesyltransferase inhibitors: where are we now? | Q37810295 |
| | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 |
| | Targeting sphingosine-1-phosphate receptors in cancer | Q37894772 |
| | Akt is a downstream target of NF-kappa B. | Q38288465 |
| | ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). | Q38476727 |
| | Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. | Q40016772 |
| | Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages | Q40306295 |
| | A Fas agonist induces high levels of apoptosis in haematological malignancies | Q40369492 |
| | Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. | Q40427915 |
| | MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly | Q40430386 |
| | Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. | Q40455268 |
| | Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. | Q40577570 |
| | Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells | Q40634373 |
| | Downregulation of Fas ligand by shedding | Q41071790 |
| | The CD95 system and the death of a lymphocyte | Q41433535 |
| | Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium | Q43003744 |
| | Expression of a Platelet-Derived Growth Factor-Like Protein in Simian Sarcoma Virus Transformed Cells | Q45797854 |
| | Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists | Q46805105 |
| | Fas ligand in human serum | Q71031959 |
| | Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia | Q74541377 |
| | Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia | Q77655163 |
| | An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects | Q80394633 |
| | Imatinib mesylate | Q82507538 |
| | Targeting STAT3 in cancer: how successful are we? | Q82824786 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 787-801 | |
| P577 | publication date | 2012-07-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets | |
| P478 | volume | 8 | |